A Canadian-headquartered biopharmaceutical company is conducting the second Phase 3 study of a new drug designed to treat prostate disease.
Aeterna Zentaris Inc. said the double-blind study to be conducted in Europe will test the clinical effectiveness of cetrorelix, a luteinizing hormone-releasing drug for the treatment of benign prostatic hyperplasia, or BPH -- a non-cancerous enlargement of the prostate that causes disturbances in urination.
In the second Phase 3 study, 400 male patients will enter a four-week, no-treatment observation period and then be randomly assigned to either receive cetrorelix or a placebo. Effectiveness will based on a test that measures the severity and stability of voiding prostate symptoms.
The company's first study of the effectiveness of cetrorelix began in April 2007 and is continuing in Canada, Europe and the United States.
Copyright 2008 by United Press International
Related stories:
Researchers demonstrate effectiveness of contrast agent Cytate in detectcing prostate cancer
Prostate cancer accounts for approximately 29 percent of cancer occurrences among men. According to "CA: A Cancer Journal for Clinicians," in 2007 it was responsible for 27,000 deaths in the United States. Early detection is important to reducing the death count.
CT lung cancer screening no cure-all for smokers
Screening for lung cancer with computed tomography (CT) may help reduce lung cancer deaths in current and former smokers, but it won't protect them from other causes of death associated with smoking, according to a new study published in the July issue of the journal
Radiology.
Blocking signaling protein prevents prostate cancer spread
Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have shown that by blocking a signaling protein, they can prevent prostate cancer cells from metastatic dissemination. The work opens the door to future studies examining the protein as a target for therapies aimed at keeping prostate cancer at bay.
Experts from 10 countries develop first evidence-based definition of lifelong premature ejaculation
International experts from ten countries have teamed up to develop the first ever evidence-based definition of lifelong premature ejaculation (PE) in the hope that it will aid future diagnosis, treatment and research.
Prostate cancer screening program leads to bigger fall in death rates than surrounding areas
The expected number of deaths from prostate cancer more than halved in the Tyrol after a programme was introduced to improve early detection and treatment of the disease, according to research published in April issue of the urology journal BJU International.
Study reveals inaccuracies in studies of cancer treatment
Certain biases may exist in observational studies that compare outcomes of different cancer therapies, making the results questionable. That is the conclusion of a new study published in the June 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The research suggests that observational studies should include more thorough information and should be better designed to minimize inaccuracies.
Screening the herbal pharmacy
Curing cancer with natural products – a case for shamans and herb women? Not at all, for many chemotherapies to fight cancer applied in modern medicine are natural products or were developed on the basis of natural substances. Thus, taxanes used in prostate and breast cancer treatment are made from yew trees. The popular periwinkle plant, which grows along the ground of many front yards, is the source of vinca alkaloids that are effective, for example, against malignant lymphomas. The modern anti-cancer drugs topotecan and irinotecan are derived from a constituent of the Chinese Happy Tree.
Protein protects lung cancer cells from efforts to fix or kill them
A protein that helps lung cancer cells thrive appears to do so by blocking healthy cells’ ability to fix themselves when radiation or chemicals such as nicotine damage their DNA, according to a University of Florida study to be published Friday (Feb. 29) in the journal
Molecular Cell.